Alessandro Rambaldi to Retrospective Studies
This is a "connection" page, showing publications Alessandro Rambaldi has written about Retrospective Studies.
Connection Strength
0.101
-
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
Score: 0.023
-
Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020 11; 225(6):152001.
Score: 0.023
-
Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis. Am J Hematol. 2019 01; 94(1):E11-E13.
Score: 0.020
-
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. Blood Cancer J. 2021 02 04; 11(2):21.
Score: 0.006
-
At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. Panminerva Med. 2021 Mar; 63(1):51-61.
Score: 0.006
-
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 09; 34(9):2354-2363.
Score: 0.006
-
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT. Eur J Cancer. 2019 01; 106:212-219.
Score: 0.005
-
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018 06; 69:100-102.
Score: 0.005
-
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts. Leukemia. 2018 05; 32(5):1200-1210.
Score: 0.005
-
Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007 Aug 01; 110(3):840-6.
Score: 0.002